Di Yi Cai Jing·2025-06-17 12:40Core Viewpoint - The establishment of "insurance系" private equity funds is driven by regulatory guidance for long-term capital market entry and the actual needs of insurance companies to adapt to a low-interest-rate environment [1][2]. Group 1: Fund Establishment and Scale - Xinhua Insurance plans to invest up to 15 billion yuan in the Honghu III private equity fund, co-established by Xinhua Asset and China Life Asset [2][3]. - Since May, at least seven "insurance系" private equity funds or products have been established, indicating a surge in activity among insurance companies [3][4]. - The Honghu III fund has a total scale of 22.5 billion yuan, with Xinhua Insurance and China Life each contributing 11.25 billion yuan [3]. Group 2: Long-term Investment Strategy - The establishment of these private equity funds reflects the results of the insurance capital's "long money long investment" strategy, driven by policy support and the need for better asset allocation in a declining interest rate environment [5]. - The long-term investment pilot program initiated in 2023 allows insurance companies to set up private equity funds primarily targeting the secondary market stocks for long-term holding [5][6]. Group 3: Investment Focus and Trends - The investment focus of these funds is expected to be on high-dividend, low-volatility stable assets, with an emphasis on companies with strong governance and good business models [10][11]. - The first phase of the Honghu fund primarily invested in key industries related to national interests, while the second phase is set to focus on large-cap A+H shares [10][11]. - Other insurance companies are also expected to follow similar investment strategies, focusing on stable, high-quality listed companies [11][12]. Group 4: Regulatory and Market Context - The pilot program for long-term investment is expected to expand by 2025, with several insurance companies already approved to participate [6][7]. - The total approved scale for the three batches of long-term investment reform trials is estimated to reach 222 billion yuan, with expectations for further increases in approved scales [7].